The Board of Directors of BioPorto A/S (“BioPorto” og the “Company”) decided on June 17, 2024 to issue 50,000,000 new shares in a private placement to existing larger shareholders, new professional ...
BioPorto A/S raises DKK 33.5 million in new capital round - Change of number of shares and votes COPENHAGEN, DENMARK, April 25, 2025 (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S ...
We successfully secured commercial availability of ProNephroTM AKI (NGAL) for the US market through our distributor. The "Forward” Strategic Plan was established in November 2025. This is a three-year ...
While BioPorto A/S (CPH:BIOPOR) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 19% in the last quarter. But at least the ...
COPENHAGEN, DENMARK and BOSTON, MA, February 22, 2024, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), today announced its preliminary results for 2023 and described its ...
Copenhagen, Denmark, November 19, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today announced interim financial results for the third quarter of 2025, unchanged ...
COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial ...
COPENHAGEN, DENMARK, March 18, 2026 - BioPorto A/S ("BioPorto” or "Company”) (CPH: BIOPOR) today announced positive clinical readout update of the preliminary analysis of its U.S. adult NGAL Cutoff ...
Hellerup, Denmark, April 15, 2019 (GLOBE NEWSWIRE) -- Today, BioPorto A/S CPH: BIOPOR ("BioPorto") announces the appointment of Amy Winslow as President for the US subsidiary, BioPorto Diagnostics, ...
COPENHAGEN, DENMARK and BOSTON, MA, USA, December 11, 2025 (GLOBE NEWSWIRE) - BioPorto A/S ("BioPorto") (CPH:BIOPOR) announced today that Niels Høy Nielsen has resigned as CFO of BioPorto to become ...
First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results